Epidermal growth factor receptor blockade: an emerging therapeutic modality in gastroenterology.

摘要: Background & Aims: The cyclooxygenase 2 (COX-2) and ErbB/HER pathways are important modulators of cancer cell growth. We sought to determine the effects treatment with a specific COX-2 inhibitor and/or monoclonal antibody against ErbB receptor subtype HER-2/neu on carcinoma Methods: A cell-proliferation assay was used response HCA-7 cells HER-3/HER-4 ligand heregulin β-1 (HRGβ-1). Both in vitro vivo assays were selective inhibitor, celecoxib, an anti-HER-2/neu (either Herceptin [Genetech Inc., S. San Francisco, CA] or 2C4) Results: express messenger RNA protein, exposure these HRGβ-1 results significant stimulation Celecoxib inhibits growth vivo. Combination therapy celecoxib plus 2C4 resulted additive that almost complete inhibition tumor Conclusions: Combined inhibitors more effectively reduces colorectal than either agent alone. Therefore, targeting both signaling may represent novel approach for prevention humans.